May. 12 at 10:58 PM
$LEXX Is a Binary Option at these levels.
Selling to save
$0.40/share risks forfeiting a 300-500% re-rating if Study #7 matches Wegovy.
With commercial-scale manufacturing done, the science risk is low—it’s a bet on management execution.
• Study #7 Catalyst: Mid-June dosing is the ultimate validator for oral GLP-1.
• Cash Runway:
$5.1M (as of Feb) bridges to Q4. A "crafty" team is unlikely to dilute at these local lows.
• "Left Field" PR: Expect a non-study update (new MTA or licensing fee) before the 5-week data to provide a valuation floor.
At a
$15M market cap, the tech is effectively free.
The risk of missing the reversal outweighs the bleed.
Doubling down before the June pump.
Wish me luck,
